Literature DB >> 11790649

Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs.

Ivan Goldstein1, Frederic Wallet, Jerome Robert, Marie-Helene Becquemin, Charles-Hugo Marquette, Jean-Jacques Rouby.   

Abstract

The tissue concentration of aminoglycosides in lung parenchyma is the main determinant of bactericidal efficiency. The aim of the study was to compare the lung deposition of amikacin administered either by an ultrasonic nebulizer or by intravenous infusion during mechanical ventilation. Eighteen healthy ventilated piglets received a single daily dose of amikacin by intravenous infusion (15 mg. kg(-1)) and 18 by aerosol (1 g in 12 ml). The amount of aerosolized amikacin reaching the tracheobronchial tree represented 40 +/- 5% of the initial dose with an aerodynamic size distribution showing 50% of particles ranging between 0.5 and 5 microm mass median diameter. Animals were killed at different time intervals after the second dose. Tissue concentrations of amikacin were determined on cryomixed multiple lung specimen by an immunoenzymatic method. The lung concentrations of nebulized amikacin, peaking at 208 +/- 76 microg. g(-1), were more than 10-fold higher than the lung concentrations of intravenous amikacin and were homogeneously distributed throughout the lung parenchyma. Amikacin plasma concentrations lower than 5 mmol. l(-1) were measured after the sixth hour after the nebulization. In conclusion, the ultrasonic nebulization of amikacin resulted in high tissue concentrations, far above the minimal inhibitory concentrations of most gram-negative strains.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790649     DOI: 10.1164/ajrccm.165.2.2107025

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  17 in total

1.  Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers.

Authors:  Fabio Ferrari; Zhi-Hai Liu; Qin Lu; Marie-Helene Becquemin; Kamel Louchahi; Guy Aymard; Charles-Hugo Marquette; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2008-04-30       Impact factor: 17.440

2.  Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa.

Authors:  Qin Lu; Cassio Girardi; Mao Zhang; Belaïd Bouhemad; Kamel Louchahi; Olivier Petitjean; Frédéric Wallet; Marie-Helene Becquemin; Gilles Le Naour; Charles-Hugo Marquette; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2010-04-16       Impact factor: 17.440

3.  Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia.

Authors:  Cassio Girardi; Marc Tonnellier; Ivan Goldstein; Alfonso Sartorius; Frederic Wallet; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2006-07-21       Impact factor: 17.440

Review 4.  Does animal model on ventilator-associated pneumonia reflect physiopathology of sepsis mechanisms in humans?

Authors:  Laura Pulido; Diego Burgos; Joaquín García Morato; Carlos M Luna
Journal:  Ann Transl Med       Date:  2017-11

Review 5.  Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.

Authors:  Garyphallia Poulakou; Dimitrios K Matthaiou; David P Nicolau; Georgios Siakallis; George Dimopoulos
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

6.  Aerosol therapy during mechanical ventilation: an international survey.

Authors:  Stephan Ehrmann; Ferran Roche-Campo; Giuseppe Francesco Sferrazza Papa; Daniel Isabey; Laurent Brochard; Gabriela Apiou-Sbirlea
Journal:  Intensive Care Med       Date:  2013-03-23       Impact factor: 17.440

Review 7.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

8.  Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.

Authors:  Fabio Ferrari; Qin Lu; Cassio Girardi; Olivier Petitjean; Charles-Hugo Marquette; Frederic Wallet; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2009-08-04       Impact factor: 17.440

9.  Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects.

Authors:  Stephan Ehrmann; Emmanuelle Mercier; Laurent Vecellio; David Ternant; Gilles Paintaud; Pierre-François Dequin
Journal:  Intensive Care Med       Date:  2007-11-29       Impact factor: 17.440

10.  Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia.

Authors:  Charles-Edouard Luyt; Marc Clavel; Kalpalatha Guntupalli; Jay Johannigman; John I Kennedy; Christopher Wood; Kevin Corkery; Dennis Gribben; Jean Chastre
Journal:  Crit Care       Date:  2009-12-10       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.